Pembrolizumab with carbon-ion radiation for advanced cervical adenocarcinoma
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests combining an immunotherapy drug (pembrolizumab) with a special type of radiation (carbon-ion radiotherapy) for a specific type of advanced cervical cancer called adenocarcinoma or adenosquamous carcinoma. It aims to see if this combination is safe and effective for patients who have not had prior radiation or chemotherapy for their cervical cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have a confirmed diagnosis of cervical adenocarcinoma or adenosquamous carcinoma.
- Your cancer must be at stage IIA2, IIB, IIIA, IIIB, IIIC1r, or IVA (advanced but not spread to distant organs).
- You cannot have had any major surgery, radiation, or chemotherapy for this cervical cancer before (a small cone biopsy is okay).
- You must have a tumor sample (from a past biopsy or a new one) that can be tested in the lab.
- You must be in generally good health, able to do most daily activities (ECOG score 0 or 1).
- You cannot have had prior treatment with drugs like pembrolizumab, nivolumab, or other immune checkpoint inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines immunotherapy (drugs that help your immune system fight cancer) with carbon ion radiation (a precise type of radiation) for people with locally advanced cervical cancer that hasn't spread to other organs. The goal is to see if this combination is safe and effective.
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
This trial tests whether adding two drugs (pembrolizumab and lenvatinib) to standard chemoradiation and brachytherapy can improve outcomes for people with high-risk locally advanced cervical cancer. It is designed for patients who are fit enough to undergo intensive treatment.
This trial tests a new combination of short-course radiation, an immunotherapy drug called adebrelimab, and standard chemotherapy before surgery for locally advanced cervical cancer. It aims to see if this approach can shrink tumors more effectively.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests a new immunotherapy drug called cadonilimab combined with radiation therapy for people with locally advanced cervical cancer who cannot receive the usual chemotherapy due to age, kidney problems, heart issues, allergies, or personal choice.
Hear when a new Cervical Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.